

Special Issue

Personalized Maternal-Fetal-Neonatal Infections: Overall Management

Message from the Guest Editors

Fetal and neonatal infections due to various microorganisms show signs and symptoms in pregnancy and in the neonatal period. During pregnancy, infections may affect the mother and the baby, and clinical manifestations may vary. Fetal infections may induce the fetal inflammatory response syndrome (FIRS) or may lead to intrauterine fetal death (IUFD). In the former, placental examination is paramount in identifying the fetal inflammatory response (FIR), and even providing the etiologic agent, through targeted microbiological cultures, helping the neonatal management. In the latter, fetal autopsy and placental examination, according to international guidelines, may also detect the infective agent and provide useful information for maternal clinical management. Early-onset neonatal sepsis is within the range of FIRS and signs and symptoms may vary, requiring prompt treatments. The different spectrum of infections during pregnancy and how they can affect the mother, the fetus and the newborn will be addressed in this Special Issue. Placental examination, and in some cases, autopsies, are fundamental in the clinical management of patients.

Guest Editors

Dr. Maria P. Bonasoni

Dr. Giancarlo Gargano

Dr. Giuseppina Comitini

Deadline for manuscript submissions

closed (15 July 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/166215

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).